Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma

Leukemia Research

Volumn 33, Issue 11, 2009, Pages 1570-1573

  Aladzsity, I ^a   Kovacs M ^a   Semsei, Á ^b   Falus, A ^b   Szilágyi, Á ^a   Karadi I ^a   Varga, G ^a   Fust G ^a   Varkonyi J ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

IL6 promoter polymorphism; IL6 receptor polymorphism; Multiple myeloma; Myelodysplasia

Indexed keywords

ALANINE; ASPARTIC ACID; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; HUMAN; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; HUMANS; INTERLEUKIN-6; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 68649097275     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.009     Document Type: Article

References (24)

1. Sfiridaki A., Miyakis S., Tsirakis G., Alegakis A., Passam A.M., Kandidaki E., et al. Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clin Chem Lab Med 43 (2005) 934-938
2. Kuku I., Bayraktar M.R., Kaya E., Erkurt M.A., Bayraktar N., Cikim K., et al. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. Mediators Inflamm 2005 (2005) 171-174
3. Alexandrakis M.G., Passam F.H., Ganotakis E.S., Sfiridaki K., Xilouri I., Perisinakis K., et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol 25 (2003) 41-46
4. Sefer D., Marisavjlevic D., Bogdanovic A., Andrejevic S., Boskovic D., Suvajdiid N., et al. Circulating interleukin-6 (IL-6) in patients with myelodysplastic syndromes. Leukemia Res 23 (1999) S23-S28 [Abstr 78]
5. Meyers C.A., Albitar M., and Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104 (2005) 788-793
6. Ershler W.B., and Keller E.T. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51 (2000) 245-270
7. Cozen W., Gebregziabher M., Conti D.V., Van Den Berg D.J., Coetzee G.A., Wang S.S., et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15 (2006) 2285-2291
8. Dring A.M., Davies F.E., Rollinson S.J., Roddam P.L., Rawstron A.C., Child J.A., et al. Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma. Br J Haematol 112 (2001) 249-251
9. Mazur G., Bogunia-Kubik K., Wrobel T., Karabon L., Polak M., Kuliczkowski K., et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 96 (2005) 241-246
10. Zheng C., Huang D.R., Bergenbrant S., Sundblad A., Osterborg A., Bjorkholm M., et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 109 (2000) 39-45
11. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
12. Duch C.R., Figueiredo M.S., Ribas C., Almeida M.S., Colleoni G.W., and Bordin J.O. Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma. Braz J Med Biol Res 40 (2007) 265-267
13. Rose-John S., Scheller J., Elson G., and Jones S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80 (2006) 227-236
14. Galicia J.C., Tai H., Komatsu Y., Shimada Y., Akazawa K., and Yoshie H. Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun 5 (2004) 513-516
15. Rafiq S., Frayling T.M., Murray A., Hurst A., Stevens K., Weedon M.N., et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun 8 (2007) 552-559
16. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102 (1998) 1369-1376
17. Olivieri F., Bonafe M., Cavallone L., Giovagnetti S., Marchegiani F., Cardelli M., et al. The -174C/G locus affects in vitro/in vivo IL-6 production during aging. Exp Gerontol 37 (2002) 309-314
18. Muller-Steinhardt M., Ebel B., and Hartel C. The impact of interleukin-6 promoter -597/-572/-174genotype on interleukin-6 production after lipopolysaccharide stimulation. Clin Exp Immunol 147 (2007) 339-345
19. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., and Ganz T. Hepcidin a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101 (2003) 2461-2463
20. Varkonyi J., Demeter J., Tordai A., and Andrikovics H. The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome. Ann Hematol 85 (2006) 869-871
21. Pietrangelo A., and Trautwein C. Mechanisms of disease: the role of hepcidin in iron homeostasis-implications for hemochromatosis and other disorders. Nat Clin Pract Gastroenterol Hepatol 1 (2004) 39-45
22. Pietrangelo A., Dierssen U., Valli L., Garuti C., Rump A., Corradini E., et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 132 (2007) 294-300
23. Varkonyi J., Tarkovacs G., Karadi I., Andrikovics H., Varga F., Varga F., et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 109 (2003) 64-67
24. Nearman Z.P., Szpurka H., Serio B., Warshawksy I., Theil K., Lichtin A., et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 82 (2007) 1076-1079